PPBT
HEALTHCAREPurple Biotech Ltd
$4.16-0.06 (-1.37%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving PPBT Today?
No stock-specific AI insight has been generated for PPBT yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.60$29.00
$4.16
Fundamentals
Market Cap$6M
P/E Ratio—
EPS$-54.00
Dividend Yield—
Dividend / Share—
ROE-1.2%
Profit Margin—
Debt / Equity—
Trading
Volume3K
Avg Volume (10D)—
Shares Outstanding929K
PPBT News
20 articles- Purple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240Yahoo Finance·Apr 27, 2026
- Purple Biotech Establishes Scientific Advisory Board to Support Development of CAPTN-3 Tri-Specific Antibody PlatformYahoo Finance·Apr 23, 2026
- Purple Biotech Announces AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody PlatformYahoo Finance·Mar 25, 2026
- Purple Biotech Regains Compliance with NasdaqYahoo Finance·Mar 17, 2026
- Purple Biotech Announces CEO TransitionYahoo Finance·Mar 13, 2026
- Purple Biotech Reports Fourth Quarter and Full Year 2025 Financial ResultsYahoo Finance·Mar 13, 2026
- Purple Biotech Announces Plan to Implement ADS Ratio ChangeYahoo Finance·Feb 25, 2026
- Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240Yahoo Finance·Jan 7, 2026
- Purple Biotech Reports Positive New Preclinical Data Demonstrating Multi-Arm Anti-Tumor Activity Across Two CAPTN-3 Tri-Specific Antibodies at ESMO Immuno-Oncology Congress 2025Yahoo Finance·Dec 11, 2025
- Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual CongressYahoo Finance·Dec 4, 2025
- Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business UpdateYahoo Finance·Nov 14, 2025
- Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 PlatformYahoo Finance·Oct 29, 2025
- Purple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor ResistanceYahoo Finance·Sep 10, 2025
- Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrantsYahoo Finance·Sep 5, 2025
- Purple Biotech Announces Pricing of Up To $18 Million Public OfferingYahoo Finance·Sep 4, 2025
- Purple Biotech Announces New Data Supporting the Unique Design of CAPTN-3 Tri-Specific Antibody IM1240 in Collaboration with the Icahn School of Medicine at Mount SinaiYahoo Finance·Sep 4, 2025
- Purple Biotech Expands CAPTN-3 Portfolio with IM1305, a Novel Tri-Specific Antibody Targeting TROP2Yahoo Finance·Sep 3, 2025
- Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceYahoo Finance·Aug 27, 2025
- Purple Biotech Reports Second Quarter 2025 Financial ResultsYahoo Finance·Aug 6, 2025
- Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025Yahoo Finance·Jul 23, 2025
All 20 articles loaded
Price Data
Open$4.18
Previous Close$4.22
Day High$4.20
Day Low$4.16
52 Week High$29.00
52 Week Low$3.60
52-Week Range
$3.60$29.00
$4.16
Fundamentals
Market Cap$6M
P/E Ratio—
EPS$-54.00
Dividend Yield—
Dividend / Share—
ROE-1.2%
Profit Margin—
Debt / Equity—
Trading
Volume3K
Avg Volume (10D)—
Shares Outstanding929K
About Purple Biotech Ltd
Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs in the United States. The company is headquartered in Rehovot, Israel.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—